Basel, 30 June 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Johannes (Hans) Clevers (1957), M.D., Ph.D., Head of Roche Pharma Research and Early Development (pRED) and member of the enlarged Corporate Executive Committee will be retiring from Roche. Hans Clevers joined the Roche Board of Directors in 2019 and then was appointed Head of Roche pRED in March 2022.
Roche CEO Thomas Schinecker: “Hans is an exceptional scientist who has been instrumental in translating cutting-edge science into improved patient outcomes. Under his leadership, the pRED organisation has accelerated several potentially transformational medicines into the final phase of development that will shape the company for the years to come. It has been a pleasure working with him and I am thankful for his many contributions to our company and patients. While he will step down from his current role at the end of August, I am grateful that he will continue to lead our Institute of Human Biology until a successor is announced.”
Barbara Schädler (1962), Head of Group Communications and member of Roche’s enlarged Corporate Executive Committee, will retire from the company at the end of the year. Barbara Schädler joined Roche in 2019.
Thomas Schinecker continued: “During more than six years at Roche, Barbara Schädler has fully integrated and modernised our company’s communication function. Communications is a core pillar representing who we are as Roche. Through Barbara’s expertise and leadership, she has successfully represented our company both internally and externally. Her resilience and determination were especially evident in her leadership during the COVID-19 pandemic when she championed our internal taskforce. I am thankful for everything that she has achieved and for our excellent collaboration.”
We will announce the successors in due course.
About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.
For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com
| Hans Trees, PhD Phone: +41 79 407 72 58 | Sileia Urech Phone: +41 79 935 81 48
|
| Nathalie Altermatt Phone: +41 79 771 05 25 | Lorena Corfas Phone: +41 79 568 24 95
|
| Simon Goldsborough Phone: +44 797 32 72 915 | Karsten Kleine Phone: +41 79 461 86 83
|
| Nina Mählitz Phone: +41 79 327 54 74 | Kirti Pandey Phone: +49 172 6367262
|
| Yvette Petillon Phone: +41 79 961 92 50 | Dr Rebekka Schnell Phone: +41 79 205 27 03 |
Attachment
- Media Release Changes to the Roche Enlarged CEC English
